Verismo Therapeutics
The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.
This is a study for the Long Term Follow Up for all participants treated with Verismo Therapeutics' SynKIR CAR T cell products in accordance with regulatory guidance. The primary objective of this study is to monitor the long-term safety of SynKIR CAR T cell products. No investigational product will be administered in this LTFU study. Eligible participants must have received at least 1 infusion of a SynKIR CAR T cell product under a Verismo Therapeutics parent protocol. Participants will be invited to enroll into this LTFU study after either early discontinuation from or completion of the par…
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: 1. All adult participants who have received any amount of SynKIR CAR T cell product in a study sponsored by Verismo Therapeutics. 2. Participant is willing and able to comply with the study requirements. Exclusion Criteria: There are no specific exclusion criteria.
Autologous T cells Transduced with Mesothelin KIR-CAR
Autologous T Cells transduced with CD19 KIR-CAR